S&P 500   4,186.15 (+1.54%)
DOW   33,253.36 (+1.46%)
QQQ   323.94 (+2.16%)
AAPL   167.89 (+1.80%)
MSFT   288.36 (+2.15%)
META   176.91 (+4.97%)
GOOGL   119.32 (+2.31%)
AMZN   142.12 (+3.11%)
TSLA   863.50 (+1.59%)
NVDA   174.79 (+2.30%)
NIO   19.76 (+3.08%)
BABA   90.50 (-0.76%)
AMD   96.76 (+1.28%)
MU   60.07 (+1.56%)
T   18.13 (+0.17%)
CGC   2.90 (+1.05%)
GE   76.25 (+1.76%)
F   15.37 (+1.18%)
DIS   110.83 (+2.50%)
AMC   21.81 (-2.85%)
PYPL   97.22 (+2.90%)
PFE   49.65 (-0.26%)
NFLX   238.57 (+3.75%)
S&P 500   4,186.15 (+1.54%)
DOW   33,253.36 (+1.46%)
QQQ   323.94 (+2.16%)
AAPL   167.89 (+1.80%)
MSFT   288.36 (+2.15%)
META   176.91 (+4.97%)
GOOGL   119.32 (+2.31%)
AMZN   142.12 (+3.11%)
TSLA   863.50 (+1.59%)
NVDA   174.79 (+2.30%)
NIO   19.76 (+3.08%)
BABA   90.50 (-0.76%)
AMD   96.76 (+1.28%)
MU   60.07 (+1.56%)
T   18.13 (+0.17%)
CGC   2.90 (+1.05%)
GE   76.25 (+1.76%)
F   15.37 (+1.18%)
DIS   110.83 (+2.50%)
AMC   21.81 (-2.85%)
PYPL   97.22 (+2.90%)
PFE   49.65 (-0.26%)
NFLX   238.57 (+3.75%)
S&P 500   4,186.15 (+1.54%)
DOW   33,253.36 (+1.46%)
QQQ   323.94 (+2.16%)
AAPL   167.89 (+1.80%)
MSFT   288.36 (+2.15%)
META   176.91 (+4.97%)
GOOGL   119.32 (+2.31%)
AMZN   142.12 (+3.11%)
TSLA   863.50 (+1.59%)
NVDA   174.79 (+2.30%)
NIO   19.76 (+3.08%)
BABA   90.50 (-0.76%)
AMD   96.76 (+1.28%)
MU   60.07 (+1.56%)
T   18.13 (+0.17%)
CGC   2.90 (+1.05%)
GE   76.25 (+1.76%)
F   15.37 (+1.18%)
DIS   110.83 (+2.50%)
AMC   21.81 (-2.85%)
PYPL   97.22 (+2.90%)
PFE   49.65 (-0.26%)
NFLX   238.57 (+3.75%)
S&P 500   4,186.15 (+1.54%)
DOW   33,253.36 (+1.46%)
QQQ   323.94 (+2.16%)
AAPL   167.89 (+1.80%)
MSFT   288.36 (+2.15%)
META   176.91 (+4.97%)
GOOGL   119.32 (+2.31%)
AMZN   142.12 (+3.11%)
TSLA   863.50 (+1.59%)
NVDA   174.79 (+2.30%)
NIO   19.76 (+3.08%)
BABA   90.50 (-0.76%)
AMD   96.76 (+1.28%)
MU   60.07 (+1.56%)
T   18.13 (+0.17%)
CGC   2.90 (+1.05%)
GE   76.25 (+1.76%)
F   15.37 (+1.18%)
DIS   110.83 (+2.50%)
AMC   21.81 (-2.85%)
PYPL   97.22 (+2.90%)
PFE   49.65 (-0.26%)
NFLX   238.57 (+3.75%)
OTCMKTS:RSPI

RespireRx Pharmaceuticals - RSPI Stock Forecast, Price & News

$0.0046
0.00 (0.00%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range
N/A
52-Week Range
$0.00
$0.03
Volume
6,000 shs
Average Volume
375,280 shs
Market Capitalization
$544,152.70
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RSPI stock logo

About RespireRx Pharmaceuticals (OTCMKTS:RSPI) Stock

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Receive RSPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RespireRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RSPI Stock News Headlines

See More Headlines
Receive RSPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RespireRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RSPI Company Calendar

Last Earnings
5/23/2022
Today
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:RSPI
Employees
2
Year Founded
N/A

Profitability

Net Income
$-3,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.10) per share

Miscellaneous

Free Float
59,761,000
Market Cap
$544,152.70
Optionable
Not Optionable
Beta
0.43

Key Executives

  • Dr. Arnold S. Lippa Ph.D. (Age 75)
    Exec. Chairman, Interim Pres, Interim CEO & Chief Scientific Officer
    Comp: $339.6k
  • Dr. Jeff Eliot Margolis (Age 66)
    Sr. VP, CFO, Treasurer, Sec. & Director
    Comp: $321.6k
  • Mr. Richard D. Purcell (Age 61)
    Sr. VP of R&D
  • Mr. David Dickason (Age 58)
    Sr. VP of Pre-Clinical Product Devel.
  • Mr. Marc M. Radin
    Controller
  • Dr. Arvid Carlsson (Age 99)
    Consultant













RSPI Stock - Frequently Asked Questions

How has RespireRx Pharmaceuticals' stock performed in 2022?

RespireRx Pharmaceuticals' stock was trading at $0.0117 at the beginning of the year. Since then, RSPI shares have decreased by 61.1% and is now trading at $0.0046.
View the best growth stocks for 2022 here
.

Are investors shorting RespireRx Pharmaceuticals?

RespireRx Pharmaceuticals saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 5,500 shares, a decrease of 37.5% from the June 30th total of 8,800 shares. Based on an average daily volume of 1,358,100 shares, the short-interest ratio is presently 0.0 days.
View RespireRx Pharmaceuticals' Short Interest
.

How were RespireRx Pharmaceuticals' earnings last quarter?

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) announced its quarterly earnings results on Monday, May, 23rd. The company reported ($0.01) earnings per share for the quarter.

What other stocks do shareholders of RespireRx Pharmaceuticals own?

What is RespireRx Pharmaceuticals' stock symbol?

RespireRx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RSPI."

How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RespireRx Pharmaceuticals' stock price today?

One share of RSPI stock can currently be purchased for approximately $0.00.

How much money does RespireRx Pharmaceuticals make?

RespireRx Pharmaceuticals (OTCMKTS:RSPI) has a market capitalization of $544,152.70.

How many employees does RespireRx Pharmaceuticals have?

RespireRx Pharmaceuticals employs 2 workers across the globe.

How can I contact RespireRx Pharmaceuticals?

RespireRx Pharmaceuticals' mailing address is 126 VALLEY ROAD SUITE C, GLEN ROCK NJ, 07452. The official website for the company is www.respirerx.com. The company can be reached via phone at (201) 444-4947, via email at jmargolis@respirerx.com, or via fax at 949-727-3657.

This page (OTCMKTS:RSPI) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.